Pesquisa de referências

Impact of digital health on the pharmaceutical industry : will business models be reshaped by digital health?

Recurso electrónico / Electronic resource
Registro MARC
Tag12Valor
LDR  00000cam a22000004b 4500
001  MAP20160014242
003  MAP
005  20160427172637.0
008  160427s2016 usa|||| ||| ||eng d
040  ‎$a‎MAP‎$b‎spa‎$d‎MAP
084  ‎$a‎931
24500‎$a‎Impact of digital health on the pharmaceutical industry‎$b‎: will business models be reshaped by digital health?
260  ‎$a‎Boston [etc.]‎$b‎Arthur D. Little‎$c‎cop. 2016
520  ‎$a‎Digital health will transform the business models of the Pharmaceutical industry. Although many companies have not yet formulated a concise Digital Health strategy, industry executives expect that by 2020, Digital Health will enable Pharmaceutical companies to activate new business segments as well as to significantly improve their competitive advantage. This is the result of a global survey conducted in the Pharmaceutical industry by Arthur D. Little and the Karlsruher Institute of Technology (KIT) to capture the current thinking and the expectations regarding the transformative impact of Digital Health. The study results indicate that by 2020 the business model of the Pharmaceutical industry will be reshaped by Digital Health
650 4‎$0‎MAPA20080539771‎$a‎Salud
650 4‎$0‎MAPA20080586546‎$a‎Nuevas tecnologías
650 4‎$0‎MAPA20140009749‎$a‎Conectividad
650 4‎$0‎MAPA20140010080‎$a‎Recursos genéticos
650 4‎$0‎MAPA20080606633‎$a‎Industria farmacéutica
650 4‎$0‎MAPA20110024864‎$a‎Modelos de negocio
650  ‎$0‎MAPA20160013733‎$a‎Salud Digital
7102 ‎$0‎MAPA20080440602‎$a‎Arthur D. Little
7102 ‎$0‎MAPA20160006001‎$a‎Karlsruher Institute of Technology